TechnoPulm

Executive Summary

TechnoPulm is an Israeli medtech company developing STS, a handheld pulmonary function testing (PFT) device that delivers comprehensive lung diagnostics—including spirometry, plethysmography, and diffusion capacity—in just 30 seconds. Leveraging patented dynamic process technology and AI-driven analysis, the device addresses the limitations of traditional bulky PFT equipment, enabling faster, more accessible testing in outpatient clinics and long-term care facilities. The company also envisions future home-use applications for telehealth, expanding respiratory monitoring beyond clinical settings. Founded in 2020 and operating in the platform stage, TechnoPulm positions itself as a disruptive solution in the pulmonology market, aiming to improve early detection and management of respiratory diseases such as COPD, asthma, and pulmonary fibrosis. With a strong value proposition in point-of-care diagnostics, TechnoPulm is well-aligned with the growing demand for decentralized healthcare and remote monitoring. The company's compact, AI-enhanced device could significantly reduce testing time and costs while increasing patient throughput. Key milestones ahead include regulatory clearances (FDA, CE marking), clinical validation studies, and strategic partnerships for distribution. As a private company with a niche focus, TechnoPulm may attract interest from larger respiratory diagnostic players seeking to augment their portfolios. However, execution risks remain around regulatory timelines and market adoption against established PFT manufacturers.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) Clearance for STS Device70% success
• Q3 2026Strategic Partnership or Distribution Agreement60% success
• Q4 2026Publication of Clinical Validation Study Results80% success